Leptomeningeal Metastases (LM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Leptomeningeal Metastases (LM) are defined as the spread of the disease to the meninges surrounding the brain and the spinal cord. They are a rare but frequently devastating complication of advanced cancer. When cancer cells are found in your leptomeninges or CSF, this is called leptomeningeal metastases (LM). LM stick onto nerves as they exit your brain and spinal cord, causing weakness and numbness. LM can also clog your leptomeninges and prevent CSF from being drained properly, causing CSF and pressure to build up inside your brain. LC is diagnosed in approximately 5% of patients with advanced cancer. However, it can be detected in up to 20% of cases in autopsy studies. LC is most frequently associated with breast cancer, lung cancer, melanoma, gastrointestinal cancer, and cancer of unknown primary. Also, it can be detected in primary brain tumors and hematologic malignancies. The prognosis of LC is poor, with median survival ranging from 4–6 weeks when untreated to 2–3 months when treated. Current treatment strategies include radiotherapy, systemic antineoplastic agents, and intrathecal chemotherapy.
Thelansis’s “Leptomeningeal Metastases
(LM) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Leptomeningeal Metastases (LM) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Leptomeningeal Metastases (LM) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Leptomeningeal Metastases (LM) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment